Medigen Vaccine Biologics マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Leo Lee

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	1.4yrs

経営陣の近況

Recent updates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

CEO（最高経営責任者

Leo Lee

less than a year

在職期間

Leo Lee is Chief Executive Officer of Medigen Vaccine Biologics Corporation.

取締役

名称	ポジション	在職期間	報酬	所有権
Chia-Hsiu Lin	Director	less than a year	NT$322.00k	データなし
Ming Cheng Chang	Chairman	9.2yrs	NT$322.00k	データなし
Tsan-Chien Chen	Director	11.9yrs	データなし	データなし
Yao-Chi Li	Independent Director	6.4yrs	NT$312.00k	データなし
Ming-Yi Wu	Independent Director	1.4yrs	データなし	データなし
Chin-Yen Chen	Representative Director	less than a year	データなし	データなし
Peng-Fei Su	Independent Director	less than a year	データなし	0.070% NT$ 8.8m

1.4yrs

平均在職期間

経験豊富なボード: 6547の取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Medigen Vaccine Biologics マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Less than half of directors are independent

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Medigen Vaccine Biologics Corporation to Report Q3, 2024 Results on Nov 04, 2024

Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024

Less than half of directors are independent

Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$3.53 loss per share (vs NT$4.56 loss in FY 2022)

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

First half 2023 earnings released: NT$1.61 loss per share (vs NT$1.41 loss in 1H 2022)

Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam

Less than half of directors are independent

Less than half of directors are independent

Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand

Third quarter 2022 earnings released: NT$0.95 loss per share (vs NT$2.16 profit in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: NT$0.97 loss per share (vs NT$0.57 loss in 2Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration

First quarter 2022 earnings released: NT$0.66 loss per share (vs NT$0.74 loss in 1Q 2021)

Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies

Medigen Vaccine Biologics Corporation Files New Drug Application (NDA) of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration

Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020)

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.75 loss in 1Q 2020)

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

New 90-day high: NT$112

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Metronic Global Berhad Provides Update on Termination of MOA with Medigen Vaccine Biologics Corporation to Obtain Exclusive Distribution Rights for MVC’s COVID-19 Vaccine

New 90-day high: NT$110

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

New 90-day high: NT$107

Metronic Global Berhad Announces Memorandum of Agreement with Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation and BlueWillow Biologics, Inc. Partners to Develop Intranasal Vaccine for SARS-CoV-2

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

New 90-day low: NT$89.40

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /04